FGFR-2 and Epithelial-Mesenchymal Transition in Endometrial Cancer
Overview
Authors
Affiliations
Background: At present, EC staging is based on the WHO conservative criteria, which only consider the percentage of gland formation. The molecular subgrouping of EC recently proposed by the Cancer Genome Atlas (TCGA) represents a milestone in precise molecular-based patient triage. The present study aimed to investigate the influence of FGFR-2 on the epithelial-mesenchymal transition (EMT) and whether it can lead to endometrial cancer dedifferentiation.
Methods: One hundred and three White female patients with confirmed EC were enrolled in our research. For the analysis, we performed next-generation sequencing and immunohistochemical analyses of E-cadherin, β-catenin, and vimentin.
Results: Tumor grade progression was closely correlated with LVI ( = 0.0338), expression of vimentin ( = 0.000), tumor budding ( = 0.000), and lack of E-cadherin ( = 0.0028). Similar observations were noted with regard to TNM/FIGO stage progression. In terms of FGFR-2 mutation, we found the following correlation -values: LVI ( = 0.069), expression of vimentin ( = 0.000), tumor budding ( = 0.000), and lack of E-cadherin ( = 0.000), RFS ( = 0.032), ECSS ( = 0.047).
Conclusions: FGFR-2 is the important factor influencing on EMT.
Lower mRNA Expression and Higher Levels of in HER2-Positive Breast Cancer.
Dix-Peek T, Dickens C, Valcarcel J, Duarte R Biology (Basel). 2024; 13(11).
PMID: 39596875 PMC: 11591975. DOI: 10.3390/biology13110920.
Modelling the complex nature of the tumor microenvironment: 3D tumor spheroids as an evolving tool.
Rodrigues D, Reis R, Pirraco R J Biomed Sci. 2024; 31(1):13.
PMID: 38254117 PMC: 10804490. DOI: 10.1186/s12929-024-00997-9.
Sankofi B, Valencia-Rincon E, Sekhri M, Ponton-Almodovar A, Bernard J, Wellberg E Front Endocrinol (Lausanne). 2023; 14:1217875.
PMID: 37800138 PMC: 10548218. DOI: 10.3389/fendo.2023.1217875.
Stogbauer F, Gess B, Brambs C, Lautizi M, Kacprowski T, Ourailidis I Cancers (Basel). 2023; 15(15).
PMID: 37568650 PMC: 10416921. DOI: 10.3390/cancers15153832.
Immune Environment and Immunotherapy in Endometrial Carcinoma and Cervical Tumors.
Laine A, Gonzalez-Lopez A, Hasan U, Ohkuma R, Ray-Coquard I Cancers (Basel). 2023; 15(7).
PMID: 37046702 PMC: 10093320. DOI: 10.3390/cancers15072042.